Journal of Clinical Psychiatry

Subject Index to Volume 48: January 1987 Through December 1987

Acetylcholine
Do benzodiazepines antagonize the actions of acetylcholine? (letter). Nov, 457
Affective Disorders
Biological markers of affective disorders and posttraumatic stress disorder: A pilot study with desipramine. Sept, 366–367
PMS and rapid-cycling BAD (letter with reply). July, 300
Serotonin-norepinephrine receptor interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders. Mar, Suppl, 12–18
Treatment of major affective disorder with fluvoxamine. Feb, 65–68
Treatment of seasonal affective disorder with morning light. Nov, 447–448
Aggression
Aggressive behavior in Huntington's disease: Treatment with propranolol. Mar, 106–108
Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient (letter). Oct, 423
Preventive aggression devices (PADS): Ambulatory restraints as an alternative to seclusion. Oct, 401–405
Agitation
Treatment of the elderly agitated patient. May, Suppl, 19–22
Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. May, 207–208
Agoraphobia
Agoraphobia and paroxysmal cerebral dysrhythmia (letter with reply). Sept, 388–389
Clonazepam: A review of open clinical trials. Oct, Suppl, 12–14
Diazepam in a patient with chronic schizophrenia complicated by agoraphobia. Jan, 33–34
Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Feb, 55–59
Three cases of overlap between panic disorder, social phobia, and agoraphobia. Nov, 452–453
Akathisia
Lithium-induced akathisia (letter). Feb, 81
Akinesia
Akinesia and postpsychotic depression: A difficult differential diagnosis. June, 240–243
Alcoholism
Alprazolam in treating secondary depression (letter with reply). Dec, 497
Diagnosis of intermediate-duration and subacute organic mental disorders in abstinent alcoholics. Aug, 319–323
Hyperactivity and the risk for alcoholism. July, 275–277
Primary and secondary depression in alcoholic men: An important distinction? Mar, 98–101
Alprazolam
A case of alprazolam, but not lorazepam, inducing manic symptoms. Mar, 117–118
Alprazolam in the treatment of posttraumatic stress disorder (letter). May, 216–217
Alprazolam in treating secondary depression (letter with reply). Dec, 497
Alprazolam treatment for panic disorder (letter with reply). July, 301
Anxiolytics and memory: A comparison of lorazepam and alprazolam. Apr, 158–160
Clonazepam versus alprazolam in the treatment of panic disorder: Interim analysis of data from a prospective, double-blind, placebo-controlled trial. Oct, Suppl, 16–19
Comparison of alprazolam and imipramine for treatment of outpatient depression. Jan, 15–19
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. Feb, 51–54
Misrepresenting uncontrolled clinical observations as 'research' (letter with reply). July, 301–302
Alzheimer's Disease
Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. May, Suppl, 9–15
Recent advances in the neurochemistry of Alzheimer's disease. May, Suppl, 23–30
Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. May, 207–208
Amantadine
A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Sept, Suppl, 20–23
Amnesia
Two cases of transient partial amnesia in the course of transient global amnesia. Nov, 449–450
Amoxapine
Amoxapine-induced cognitive impairment in two patients. Apr, 166–167
Anorexia Nervosa
Anorexia nervosa in a young man with Tourette's syndrome (letter with reply). Mar, 123
Antibodies, Viral
Viral antibodies and interferon in acute psychiatric disorders. May, 194–196
Anticholinergic Agents
A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Sept, Suppl, 20–23
Antidepressive Agents: See also specific drugs and Tricyclic Antidepressants
Antidepressant drug therapy for bulimia: Current status revisited (letter). Sept, 385
Clinical experience with serotonin reuptake inhibiting antidepressants. Mar, Suppl, 26–30
Effects of minor tranquilizers and antidepressants on psychomotor performance. Dec, Suppl, 22–28
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. Feb, 51–54
Management of antidepressant-induced side effects: A practical guide for the clinician. Jan, 3–8
Pharmacologic properties of serotonergic agents and antidepressant drugs. Mar, Suppl, 5–11
Antiparkinson Drugs: See also specific drugs
A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Sept, Suppl, 20–23
Antipsychotic Agents see Tranquilizing Agents, Major
Anxiety
Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: A double-blind trial. Sept, 355–358
Effect of clorazepate on depressed mood in anxious patients. Jan, 13–14
Medical evaluation of panic attacks. Aug, 309–313
Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. Oct, Suppl, 22–26
Serum pseudocholinesterase in state anxiety. May, 204–206
Anxiolytic Agents see Tranquilizing Agents, Minor
Aspirin
Aspirin does not significantly affect patients' serum lithium levels (letter). Oct, 425
Attention Deficit Disorder
Attention deficit disorder and pathological gambling. Dec, 487–488
Cocaine abuse and adult attention deficit disorder. Sept, 376–377
The effect of methylphenidate on school grades in children with attention deficit disorder without hyperactivity: A preliminary report. Mar, 112–114
Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine (letter with reply). Nov, 456
Autoradiography
Receptor alterations associated with serotonergic agents: An autoradiographic analysis. Mar, Suppl, 19–25
Behavioral Disturbances
Behavioral toxicity of antipsychotic drugs. Sept, Suppl, 13–19
Behavioral Symptoms
Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. May, Suppl, 9–15
Benzodiazepines: See also specific drugs
Accident- and injury-related health-care utilization among benzodiazepine users and nonusers. Dec, Suppl, 17–21
Do benzodiazepines antagonize the actions of acetylcholine? (letter). Nov, 457
Long-term anxiolytic therapy: The issue of drug withdrawal. Dec, Suppl, 12–16
Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. Oct, Suppl, 22–26
Seizures following triazolam withdrawal despite benzodiazepine treatment. Oct, 418–419
Two cases of benzodiazepine toxicity in children. Nov, 450–452
Withdrawal and detoxification from benzodiazepine dependence: A potential role for clonazepam. Oct, Suppl, 43–48

Journal of Clinical Psychiatry

Subject Index to Volume 48: January 1987 Through December 1987

Acetylcholine
Do benzodiazepines antagonize the actions of acetylcholine? (letter). Nov, 457
Affective Disorders
Biological markers of affective disorders and posttraumatic stress disorder: A pilot study with desipramine. Sept, 366–367
PMS and rapid-cycling BAD (letter with reply). July, 300
Serotonin-norepinephrine receptor interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders. Mar, Suppl, 12–18
Treatment of major affective disorder with fluvoxamine. Feb, 65–68
Treatment of seasonal affective disorder with morning light. Nov, 447–448
Aggression
Aggressive behavior in Huntington's disease: Treatment with propranolol. Mar, 106–108
Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient (letter). Oct, 423
Preventive aggression devices (PADS): Ambulatory restraints as an alternative to seclusion. Oct, 401–405
Agitation
Treatment of the elderly agitated patient. May, Suppl, 19–22
Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. May, 207–208
Agoraphobia
Agoraphobia and paroxysmal cerebral dysrhythmia (letter with reply). Sept, 388–389
Clonazepam: A review of open clinical trials. Oct, Suppl, 12–14
Diazepam in a patient with chronic schizophrenia complicated by agoraphobia. Jan, 33–34
Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Feb, 55–59
Three cases of overlap between panic disorder, social phobia, and agoraphobia. Nov, 452–453
Akathisia
Lithium-induced akathisia (letter). Feb, 81
Akinesia
Akinesia and postpsychotic depression: A difficult differential diagnosis. June, 240–243
Alcoholism
Alprazolam in treating secondary depression (letter with reply). Dec, 497
Diagnosis of intermediate-duration and subacute organic mental disorders in abstinent alcoholics. Aug, 319–323
Hyperactivity and the risk for alcoholism. July, 275–277
Primary and secondary depression in alcoholic men: An important distinction? Mar, 98–101
Alprazolam
A case of alprazolam, but not lorazepam, inducing manic symptoms. Mar, 117–118
Alprazolam in the treatment of posttraumatic stress disorder (letter). May, 216–217
Alprazolam in treating secondary depression (letter with reply). Dec, 497
Alprazolam treatment for panic disorder (letter with reply). July, 301
Anxiolytics and memory: A comparison of lorazepam and alprazolam. Apr, 158–160
Clonazepam versus alprazolam in the treatment of panic disorder: Interim analysis of data from a prospective, double-blind, placebo-controlled trial. Oct, Suppl, 16–19
Comparison of alprazolam and imipramine for treatment of outpatient depression. Jan, 15–19
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. Feb, 51–54
Misrepresenting uncontrolled clinical observations as 'research' (letter with reply). July, 301–302
Alzheimer's Disease
Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. May, Suppl, 9–15
Recent advances in the neurochemistry of Alzheimer's disease. May, Suppl, 23–30
Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. May, 207–208
Amantadine
A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Sept, Suppl, 20–23
Amnesia
Two cases of transient partial amnesia in the course of transient global amnesia. Nov, 449–450
Amoxapine
Amoxapine-induced cognitive impairment in two patients. Apr, 166–167
Anorexia Nervosa
Anorexia nervosa in a young man with Tourette's syndrome (letter with reply). Mar, 123
Antibodies, Viral
Viral antibodies and interferon in acute psychiatric disorders. May, 194–196
Anticholinergic Agents
A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Sept, Suppl, 20–23
Antidepressive Agents: See also specific drugs and Tricyclic Antidepressants
Antidepressant drug therapy for bulimia: Current status revisited (letter). Sept, 385
Clinical experience with serotonin reuptake inhibiting antidepressants. Mar, Suppl, 26–30
Effects of minor tranquilizers and antidepressants on psychomotor performance. Dec, Suppl, 22–28
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. Feb, 51–54
Management of antidepressant-induced side effects: A practical guide for the clinician. Jan, 3–8
Pharmacologic properties of serotonergic agents and antidepressant drugs. Mar, Suppl, 5–11
Antiparkinson Drugs: See also specific drugs
A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Sept, Suppl, 20–23
Antipsychotic Agents see Tranquilizing Agents, Major
Anxiety
Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: A double-blind trial. Sept, 355–358
Effect of clorazepate on depressed mood in anxious patients. Jan, 13–14
Medical evaluation of panic attacks. Aug, 309–313
Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. Oct, Suppl, 22–26
Serum pseudocholinesterase in state anxiety. May, 204–206
Anxiolytic Agents see Tranquilizing Agents, Minor
Aspirin
Aspirin does not significantly affect patients' serum lithium levels (letter). Oct, 425
Attention Deficit Disorder
Attention deficit disorder and pathological gambling. Dec, 487–488
Cocaine abuse and adult attention deficit disorder. Sept, 376–377
The effect of methylphenidate on school grades in children with attention deficit disorder without hyperactivity: A preliminary report. Mar, 112–114
Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine (letter with reply). Nov, 456
Autoradiography
Receptor alterations associated with serotonergic agents: An autoradiographic analysis. Mar, Suppl, 19–25
Behavioral Disturbances
Behavioral toxicity of antipsychotic drugs. Sept, Suppl, 13–19
Behavioral Symptoms
Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. May, Suppl, 9–15
Benzodiazepines: See also specific drugs
Accident- and injury-related health-care utilization among benzodiazepine users and nonusers. Dec, Suppl, 17–21
Do benzodiazepines antagonize the actions of acetylcholine? (letter). Nov, 457
Long-term anxiolytic therapy: The issue of drug withdrawal. Dec, Suppl, 12–16
Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. Oct, Suppl, 22–26
Seizures following triazolam withdrawal despite benzodiazepine treatment. Oct, 418–419
Two cases of benzodiazepine toxicity in children. Nov, 450–452
Withdrawal and detoxification from benzodiazepine dependence: A potential role for clonazepam. Oct, Suppl, 43–48

Biological Markers
Biological markers of affective disorders and posttraumatic stress disorder: A pilot study with desipramine. Sept, 366–367
Methylene blue: A reliable and practical marker for validating compliance on the DST. June, 224–229

Bipolar Disorder
Clonazepam in acute and maintenance treatment of bipolar affective disorder. Oct, Suppl, 29–36
Clonazepam in the treatment of bipolar disorder in patients with non-lithium-induced renal insufficiency (letter). Oct, 424
PMS and rapid-cycling BAD (letter with reply). July, 300

Blacks
Hypertension in the black population (letter). Sept, 387

Blood Levels
Aspirin does not significantly affect patients' serum lithium levels (letter). Oct, 425
Correction of lithium levels for dose and blood sampling times. Feb, 60–64
Ibuprofen can increase serum lithium level in lithium-treated patients. Apr, 161–163
Serum neuroleptic levels, prolactin levels, and relapse: A two-year study of schizophrenic outpatients. Apr, 151–154
Serum potassium levels and adrenergic activation (letter). Nov, 457

Book Reviews
Criteria for Review—And the Joys of a Book Review Editor (Akiskal). July, 297–298
The New Biopsychiatry: A Review of Selected Literature (Akiskal). Sept, 382–384

Books Reviewed
APA Office of Economic Affairs: An Economic Survival Manual for Private Practice Psychiatrists. Jan, 37
Barker P: Basic Family Therapy, 2nd Ed. Dec, 495
Baroff GS: Mental Retardation: Nature, Cause, and Management, 2nd Ed. Nov, 454
Beahrs JD: Limits of Scientific Psychiatry: The Role of Uncertainty in Mental Health. Dec, 494
Bloch S, Crouch E: Therapeutic Factors in Group Psychotherapy. Feb, 80
Bluhm J: When You Face the Chemically Dependent Patient: A Practical Guide for Nurses. Dec, 494
Bulhan HA: Frantz Fanon and the Psychology of Oppression. Jan, 36-37
Butcher JN (ed): Computerized Psychological Assessment. Dec, 495
Casey DE, Chase TN, Christensen AV, Gerlach J (eds): Dyskinesia: Research and Treatment (Psychopharmacology Supplementum 2). Jan, 35
Cermak TL: Diagnosing and Treating Co-Dependence: A Guide for Professionals Who Work With Chemical Dependents, Their Spouses, and Children. Oct, 421
Christodoulou GN (ed): The Delusional Misidentification Syndromes. Mar, 122
Dotevall G: Stress and Common Gastrointestinal Disorders: A Comprehensive Approach. Jan, 35–36
Evered D, Clark S (eds): Photoperiodism, Melatonin, and the Pineal. June, 253
Filskov SG, Boll TJ (eds): Handbook of Clinical Neuropsychology, Vol. 2. Apr, 172
Frame J: An Angel at My Table. Apr, 171
Freedman DX, Lourie RS, Meltzer HY, et al: 1986 Year Book of Psychiatry and Applied Mental Health. Oct, 422
Gilbert S: Pathology of Eating: Psychology and Treatment. Oct, 421–422
Glenn MD, Weiner RD: Electroconvulsive Therapy: A Programmed Text. Jan, 36
Goodwin DW: Anxiety. Jan, 35
Greenberg M, Szmukler G, Tantam D: Making Sense of Psychiatric Cases. May, 212–213
Inwood DG (ed): Recent Advances in Postpartum Psychiatric Disorders. Mar, 121
Jenike MA: Handbook of Geriatric Psychopharmacology. Oct, 422
Johnson VE: Intervention: How To Help Someone Who Doesn't Want Help. Aug, 342–343
Kirshner HS: Behavioral Neurology: A Practical Approach. Aug, 343
Larocca FEF (ed): Eating Disorders: Effective Care and Treatment. Nov, 455
Lazarus JH, Collard KJ: Endocrine and Metabolic Effects of Lithium. Mar, 121–122
Livesey PJ: Learning and Emotion: A Biological Synthesis, Vol. 1: Evolutionary Processes. Nov, 455
Maltsberger JT: Suicide Risk: The Formulation of Clinical Judgment. Nov, 454
Millon T, Klerman GL (eds): Contemporary Directions in Psychopathology: Toward the DSM-IV. Aug, 342
Mueller WJ, Aniskiewicz AS: Psychotherapeutic Intervention in Hysterical Disorders. Feb, 80
Pedersen P (ed): Handbook of Cross-Cultural Counseling and Therapy. Jan, 37
Rippere V, Williams R (eds): Wounded Healers: Mental Health Workers' Experiences of Depression. Apr, 171
Russell ML: Behavioral Counseling in Medicine. Mar, 121
Schwartz MF, Carter GL: You Can Stop Stuttering. Feb, 79
Scott CD, Hawk J (eds): Heal Thyself: The Health of Health Care Professionals. May, 211–212
Simon RI: Clinical Psychiatry and the Law. June, 254
Stimmel B (ed): Controversies in Alcoholism and Substance Abuse. Apr, 171–172
Wallerstein RS: Forty-Two Lives in Treatment: A Study of Psychoanalysis and Psychotherapy. May, 211
Wattis J and Church M: Practical Psychiatry of Old Age. Oct, 422
Weiner MF: Practical Psychotherapy. June, 254
Westermeyer J: A Clinical Guide to Alcohol and Drug Problems. Oct, 421
Will D, Wrate RM: Integrated Family Therapy: A Problem-Centered Psychodynamic Approach. Feb, 79–80
Wilson RR: Don't Panic: Taking Control of Anxiety Attacks. June, 253–254
Winokur G, Clayton P (eds): The Medical Basis of Psychiatry. Nov, 454

Borderline Personality Disorder
Characterizing depression in borderline patients. Apr, 155–157
Current overview of the borderline diagnosis. Aug, Suppl, 5–11
Introduction: The borderline patient. Aug, Suppl, 3–4
Is bulimia associated with borderline personality disorder? A controlled study. May, 181–184
Neuroleptic treatment in the borderline patient: Advantages and techniques. Aug, Suppl, 26–30
Psychopharmacology of borderline personality disorder: A review. Aug, Suppl, 15–22
Treatment of outpatients with borderline personality disorder. Aug, Suppl, 32–35

Brain
Anterior cortical atrophy in Fregoli syndrome. Oct, 409–411
Clonazepam pharmacokinetics, brain uptake, and receptor interactions. Oct, Suppl, 4–9

Bromocriptine
Bromocriptine treatment of neuroleptic malignant syndrome. Feb, 69–73
Cocaine abuse and adult attention deficit disorder. Sept, 376–377

Bulimia see Hyperphagia

Buspirone
Antianxiety therapy: Potential value of long-term treatment. Dec, Suppl, 7–11
Buspirone in the long-term treatment of generalized anxiety disorder. Dec, Suppl, 3–6
Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. May, 201–203
Long-term anxiolytic therapy: The issue of drug withdrawal. Dec, Suppl, 12–16

Canker Sore see Stomatitis Aphthous

Capgras Syndrome
Capgras' syndrome: The delusion of substitution. Apr, 147–150

Carbamazepine
Carbamazepine, diuretics, and hyponatremia: A possible interaction. July, 281–283
Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient (letter). Oct, 423
Carbamazepine in frontal lobe syndrome: Two more cases (letter). Nov, 456
Carbamazepine treatment for stuttering (letter). Jan, 39
Carbamazepine versus lithium in mania: A double-blind study. Mar, 89–93
Erythema multiforme major in a patient treated with carbamazepine. Oct, 416–417
Hyponatremic effect of carbamazepine (letter with reply). Apr, 173
Successful treatment course with carbamazepine despite initial significant leukopenia: Case report. Aug, 338–339

Cardiac Side Effects
Complete heart block associated with mesoridazine and lithium combination (letter). Mar, 123
Lithium-related atrial premature contractions (letter). July, 305

Catatonia
A case of catatonia induced by bacterial meningoencephalitis. Dec, 489–490
A case of nonneuroleptic malignant syndrome. July, 287–288

Children
Clonazepam in the treatment of prepubertal children with panic-like symptoms. Oct, Suppl, 38–41
P.R.N. medications in child state hospital inpatients. Sept, 351–354
Two cases of benzodiazepine toxicity in children. Nov, 450–452

Chlordiazepoxide
Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: A double-blind trial. Sept, 355–358

Chlorpromazine
Priapism associated with thiothixene, chlorpromazine, and thioridazine (letter). May, 216

Chromosomes
An XX male with schizophrenia: A case of personality development and illness similar to that in XXY males. Sept, 379–380

Clonazepam
Clonazepam: A review of open clinical trials. Oct, Suppl, 12–14
Clonazepam in acute and maintenance treatment of bipolar affective disorder. Oct, Suppl, 29–36
Clonazepam in the treatment of prepubertal children with panic-like symptoms. Oct, Suppl, 38–41
Clonazepam in the treatment of bipolar disorder in patients with non-lithium-induced renal insufficiency (letter). Oct, 424
Clonazepam: New uses and potential problems. Oct, Suppl, 50–55
Clonazepam pharmacokinetics, brain uptake, and receptor interactions. Oct, Suppl, 4–9
Clonazepam versus alprazolam in the treatment of panic disorder: Interim analysis of data from a prospective, double-blind, placebo-controlled trial. Oct, Suppl, 16–19
New uses for clonazepam in psychiatry: Concluding remarks. Oct, Suppl, 56
New uses for clonazepam in psychiatry: Introduction and overview. Oct, Suppl, 3
Withdrawal and detoxification from benzodiazepine dependence: A potential role for clonazepam. Oct, Suppl, 43–48

Clorazepate
Effect of clorazepate on depressed mood in anxious patients. Jan, 13–14

Clozapine
Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. July, 263–267

CME Tests
CME Tests. May, Suppl, 31–32

Cocaine
A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. Nov, 442–444
Blunting of TSH response to TRH in chronic cocaine and phencyclidine abusers. Jan, 25–26
Cocaine abuse and adult attention deficit disorder. Sept, 376–377
Eating disorders and cocaine abuse: A survey of 259 cocaine abusers. Feb, 47–50
Cognition Disorders
Amoxapine-induced cognitive impairment in two patients. Apr, 166–167
Cognitive disabilities: Measuring the social consequences of mental disorders. May, 185–190
Cognition, Tests of
The Modified Mini-Mental (3MS) Examination. Aug, 314–318
Compliance
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. Feb, 51–54
Methylene blue: A reliable and practical marker for validating compliance on the DST. June, 224–229
Computed Tomography
Anterior cortical atrophy in Fregoli syndrome. Oct, 409–411
Continuation Treatment see Maintenance Treatment
Corrections
Glazer WM, Maynard C, Berkman CS: Injection site leakage of depot neuroleptics: Intramuscular versus subcutaneous injection (48:237). Oct, 425
Cough
Psychogenic habit cough: Review and case reports. Dec, 483–486
Delayed-Action Preparations
Injection site leakage of depot neuroleptics: Intramuscular versus subcutaneous injection; correction. Oct, 425, June, 237–239
Delirium
A case of psychosis and delirium following withdrawal from triazolam. Apr, 168–169
Delirium and the resolution of depression. Sept, 373–375
Myoclonus and episodic delirium associated with phenelzine: A case report. Aug, 340–341
Postcardiotomy confusion and sleep loss. Nov, 445–446
Dementia
Classification of depression and dementia in the elderly (letter). Aug, 344
Dementia and antipsychotic drugs. May, Suppl, 16–18
Dementia syndromes: Neurobehavioral and neuropsychiatric features. May, Suppl, 3–8
Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia. Sept, 368–370
Depot Preparations see Delayed-Action Preparations
Depression: See also Bipolar Disorder
A comparison of self-reported versus clinician-rated symptoms in depression. June, 246–248
A fixed-dose clinical trial of fluoxetine in outpatients with major depression. Oct, 406–408
Akinesia and postpsychotic depression: A difficult differential diagnosis. June, 240–243
Alprazolam in treating secondary depression (letter with reply). Dec, 497
Characterizing depression in borderline patients. Apr, 155–157
Classification of depression and dementia in the elderly (letter). Aug, 344
Comparison of alprazolam and imipramine for treatment of outpatient depression. Jan, 15–19
Delirium and the resolution of depression. Sept, 373–375
Effect of clorazepate on depressed mood in anxious patients. Jan, 13–14
High-dosage tranylcypromine in refractory depression (letter). Oct, 424–425
Major depression: Diagnostic problems and misconceptions (letter). June, 255–256
Metoclopramide and depression (letter with reply). Jan, 38
Pretreatment dexamethasone suppression test as a predictor of response to phenelzine. Dec, 480–482
Primary and secondary depression in alcoholic men: An important distinction? Mar, 98–101
Prognostic validity of self-report and interview measures of personality disorder in depressed patients. Dec, 468–472
Recurrent depression: An assessment of family burden and family attitudes. Oct, 395–400
Refractory depression treated with high doses of a monoamine oxidase inhibitor. Jan, 31–32
Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. May, 197–200
Response to treatment in primary and secondary depression (letter). Sept, 386–387
Sleep apnea and hypothyroidism presenting as depression in two patients. Apr, 164–165
The effect of desipramine on body weight in depression. Jan, 27–28
Tranylcypromine treatment of major depression (letter with reply). July, 303
Treatment and outcome in secondary depression: A naturalistic study of 1087 patients. Nov, 438–441
Triazolam-induced brief episodes of secondary mania in a depressed patient. Dec, 492–493
Depressive Disorder
Physical complaints are part of the core depressive syndrome: Evidence from a cross-cultural study in Israel. Apr, 140–142
Desipramine
A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. Nov, 442–444
Biological markers of affective disorders and posttraumatic stress disorder: A pilot study with desipramine. Sept, 366–367
Desipramine and phenytoin: A potential drug interaction of therapeutic relevance (letter). Sept, 387–388
Desipramine and weight gain (letter). Dec, 498–499
Testicular swelling associated with desipramine. June, 251–252
The effect of desipramine on body weight in depression. Jan, 27–28
Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine (letter with reply). Nov, 456
Dexamethasone Suppression Test
Methylene blue: A reliable and practical marker for validating compliance on the DST. June, 224–229
Pretreatment dexamethasone suppression test as a predictor of response to phenelzine. Dec, 480–482
Dextroamphetamine
Dextroamphetamine treatment of mania. Oct, 412–413
Diabetes Insipidus
Coexisting central diabetes insipidus and psychogenic polydipsia. Feb, 75–76
Diagnosis/Classification
Classification of depression and dementia in the elderly (letter). Aug, 344
Diagnosis of intermediate-duration and subacute organic mental disorders in abstinent alcoholics. Aug, 319–323
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. Feb, 51–54
Major depression: Diagnostic problems and misconceptions (letter). June, 255–256
Medical evaluation of panic attacks. Aug, 309–313
The reassessment of chronic patients previously diagnosed as schizophrenic. Nov, 430–434
Diazepam
Diazepam in a patient with chronic schizophrenia complicated by agoraphobia. Jan, 33–34
Treatment of coexistent night-terrors and somnambulism in adults with imipramine and diazepam. May, 209–210
Dietary Aids
MAOI reaction with powdered protein dietary supplement (letter). Dec, 499
Differential Diagnosis
A case of parasomnia at REM sleep onset. Oct, 414–415
Akinesia and postpsychotic depression: A difficult differential diagnosis. June, 240–243
Dementia syndromes: Neurobehavioral and neuropsychiatric features. May, Suppl, 3–8
Diuretics
Carbamazepine, diuretics, and hyponatremia: A possible interaction. July, 281–283
Dopamine
Cocaine abuse and adult attention deficit disorder. Sept, 376–377
Drug Abuse see Substance Abuse
Drug Administration Routes
Clinical effectiveness of oral and parenteral rapid neuroleptization. Jan, 20–24
Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. Mar, 94–97
Decreased extrapyramidal symptoms with intravenous haloperidol. July, 278–280
Drug Administration Schedules
P.R.N. medications in child state hospital inpatients. Sept, 351–354
Drug Interactions
Carbamazepine, diuretics, and hyponatremia: A possible interaction. July, 281–283
Desipramine and phenytoin: A potential drug interaction of therapeutic relevance (letter). Sept, 387–388
Hypomania related to phenelzine and isoetharine interaction in one patient. Apr, 170
Lithium-verapamil: Further considerations (letter). Mar, 124
Verapamil: A new antimanic drug with potential interactions with lithium. Sept, 371–372
Drug Withdrawal Phenomena
Long-term anxiolytic therapy: The issue of drug withdrawal. Dec, Suppl, 12–16
Withdrawal and detoxification from benzodiazepine dependence: A potential role for clonazepam. Oct, Suppl, 43–48
Dyskinesia, Drug-Induced
Piracetam for drug-induced dyskinesia (letter). June, 255
Eating Disorders: See also Anorexia Nervosa and Hyperphagia
Eating disorders and cocaine abuse: A survey of 259 cocaine abusers. Feb, 47–50
Hyperprolactinemia in two patients with eating disorders. Mar, 119–120
Editorials
Passage: An Editor in Chief. June, 223
Sail into the future. July, 262
Electroconvulsive Therapy
ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. Mar, 102–105
Mania associated with electroconvulsive therapy (letter with reply). July, 303–304
Resolution of hyperthyroidism after ECT therapy (letter with reply). July, 304–305
Treatment of mania: A naturalistic study of electroconvulsive therapy versus lithium in 438 patients. Apr, 132–139
Unilateral brief-pulse ECT and bilateral sinusoidal ECT (letter with reply). Jan, 38
Electroencephalography
Agoraphobia and paroxysmal cerebral dysrhythmia (letter with reply). Sept, 388–389
Emergency Services, Psychiatric
Patients who bring weapons to the psychiatric emergency room. June, 230–233
Epidemiology
Clinical epidemiology of suicide. Dec, Suppl, 33–38
Lest treatment abet suicide. Dec, Suppl, 44–54
Erythema Multiforme
Erythema multiforme major in a patient treated with carbamazepine. Oct, 416–417

Etiologic Studies
Comparison of severe and mild tardive dyskinesia: Implications for etiology. Sept, 359–362

Extrapyramidal Side Effects
Decreased extrapyramidal symptoms with intravenous haloperidol. July, 278–280
Extrapyramidal side effects: A historical perspective. Sept, Suppl, 3–6
Legal liability with psychotropic drug use: Extrapyramidal syndromes and tardive dyskinesia. Sept, Suppl, 28–33
Neuropharmacology of the extrapyramidal system. Sept, Suppl, 7–12
Treating extrapyramidal reactions: Some current issues. Sept, Suppl, 24–27

Family
Recurrent depression: An assessment of family burden and family attitudes. Oct, 395–400

Fluoxetine
A fixed-dose clinical trial of fluoxetine in outpatients with major depression. Oct, 406–408

Fluvoxamine
Treatment of major affective disorder with fluvoxamine. Feb, 65–68

Forensic Psychiatry
Assessing dangerousness and responding appropriately: Hedlund expands the clinician's liability established by Tarasoff. Jan, 9–12
Consent and liability: Special problems with anxiolytics. Dec, Suppl, 29–32
Legal liability with psychotropic drug use: Extrapyramidal syndromes and tardive dyskinesia. Sept, Suppl, 28–33

Fregoli's Syndrome
Anterior cortical atrophy in Fregoli syndrome. Oct, 409–411

Gambling
Attention deficit disorder and pathological gambling. Dec, 487–488
Impotence associated with compulsive gambling. Mar, 115–116

Generalized Anxiety Disorder
Antianxiety therapy: Potential value of long-term treatment. Dec, Suppl, 7–11
Buspirone in the long-term treatment of generalized anxiety disorder. Dec, Suppl, 3–6
Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. May, 201–203

Geriatric Patients
Classification of depression and dementia in the elderly (letter). Aug, 344
Effectiveness of neuroleptics on behavioral symptoms in disturbed elderly patients (letter with reply). Dec, 497–498
Management of behavioral symptoms in disturbed elderly patients: Comparison of trifluoperazine and haloperidol. June, 234–236
Treatment of the elderly agitated patient. May, Suppl, 19–22

Gilles de la Tourette's Disease
Anorexia nervosa in a young man with Tourette's syndrome (letter with reply). Mar, 123
Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine (letter with reply). Nov, 456

Haloperidol
Decreased extrapyramidal symptoms with intravenous haloperidol. July, 278–280
Management of behavioral symptoms in disturbed elderly patients: Comparison of trifluoperazine and haloperidol. June, 234–236
Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. Sept, 363–365

Hansen's Disease see Leprosy

Head Injury
Manic syndrome following head injury: Another form of secondary mania. Jan, 29–30

Huntington's Chorea
Aggressive behavior in Huntington's disease: Treatment with propranolol. Mar, 106–108
Paradoxical aggressive effect of propranolol in a patient with Huntington's disease (letter). Sept, 385–386

Hydergine
Hydergine for schizophrenia (letter). Jan, 39–40

Hyperactivity
Hyperactivity and the risk for alcoholism. July, 275–277

Hyperphagia
Antidepressant drug therapy for bulimia: Current status revisited (letter). Sept, 385
Is bulimia associated with borderline personality disorder? A controlled study. May, 181–184

Hyperprolactinemia
Hyperprolactinemia in two patients with eating disorders. Mar, 119–120

Hypertension
Hypertension in the black population (letter). Sept, 387
Mysterious hypertensive episodes (letter with reply). July, 304

Hyperthyroidism
Resolution of hyperthyroidism after ECT therapy (letter with reply). July, 304–305
The problem with parsimony: Mania and hyperthyroidism. July, 289–290

Hyperventilation
Hyperventilation and panic attacks. Nov, 435–437

Hypokalemia
Serum potassium levels and adrenergic activation (letter). Nov, 457

Hyponatremia
Carbamazepine, diuretics, and hyponatremia: A possible interaction. July, 281–283
Hyponatremic effect of carbamazepine (letter with reply). Apr, 173

Hypothyroidism
Sleep apnea and hypothyroidism presenting as depression in two patients. Apr, 164–165

Ibuprofen
Ibuprofen can increase serum lithium level in lithium-treated patients. Apr, 161–163

Imipramine
An outpatient evaluation of phenelzine and imipramine. Apr, 143–146
Comparison of alprazolam and imipramine for treatment of outpatient depression. Jan, 15–19
Imipramine and tinnitus. Mar, 109–111
Imipramine and tinnitus (letters with reply). Dec, 496
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. Feb, 51–54
Treatment of coexistent night-terrors and somnambulism in adults with imipramine and diazepam. May, 209–210
Treatment of major affective disorder with fluvoxamine. Feb, 65–68

Impotence
Impotence associated with compulsive gambling. Mar, 115–116

Injections, Intramuscular
Injection site leakage of depot neuroleptics: Intramuscular versus subcutaneous injection. June, 237–239; correction, Oct, 425

Injections, Subcutaneous
Injection site leakage of depot neuroleptics: Intramuscular versus subcutaneous injection. June, 237–239; correction, Oct, 425

Insomnia
Postcardiotomy confusion and sleep loss. Nov, 445–446

Interferon
Viral antibodies and interferon in acute psychiatric disorders. May, 194–196

Interviews
Prognostic validity of self-report and interview measures of personality disorder in depressed patients. Dec, 468–472
Suicide risk prediction by computer interview: A prospective study. Dec, 464–467

Irritable Bowel Syndrome
Verapamil in the treatment of irritable bowel syndrome (letter). Sept, 388

Isoetharine
Hypomania related to phenelzine and isoetharine interaction in one patient. Apr, 170

Israel
Physical complaints are part of the core depressive syndrome: Evidence from a cross-cultural study in Israel. Apr, 140–142

Laboratory Analyses
Neuroleptic malignant syndrome: Physiological and laboratory findings in a series of nine cases. Aug, 328–333

Leprosy
Psychiatric aspects of Hansen's disease (leprosy). Dec, 477–479

Leukopenia
Successful treatment course with carbamazepine despite initial significant leukopenia: Case report. Aug, 338–339

Lithium
Aspirin does not significantly affect patients' serum lithium levels (letter). Oct, 425
Carbamazepine versus lithium in mania: A double-blind study. Mar, 89–93
Complete heart block associated with mesoridazine and lithium combination (letter). Mar, 123
Correction of lithium levels for dose and blood sampling times. Feb, 60–64
Ibuprofen can increase serum lithium level in lithium-treated patients. Apr, 161–163
Lithium-induced akathisia (letter). Feb, 81
Lithium-related atrial premature contractions (letter). July, 305
Lithium-verapamil: Further considerations (letter). Mar, 124
Prediction of therapeutic lithium dose: Comparison and improvement of current methods. July, 284–286
Treatment of mania: A naturalistic study of electroconvulsive therapy versus lithium in 438 patients. Apr, 132–139
Verapamil: A new antimanic drug with potential interactions with lithium. Sept, 371–372

Lorazepam
A case of alprazolam, but not lorazepam, inducing manic symptoms. Mar, 117–118
Anxiolytics and memory: A comparison of lorazepam and alprazolam. Apr, 158–160

Maintenance Treatment: See also Continuation Treatment
Clonazepam in acute and maintenance treatment of bipolar affective disorder. Oct, Suppl, 29–36

Manic Disorder
A case of alprazolam, but not lorazepam, inducing manic symptoms. Mar, 117–118
Carbamazepine versus lithium in mania: A double-blind study. Mar, 89–93
Dextroamphetamine treatment of mania. Oct, 412–413
Hypomania related to phenelzine and isoetharine interaction in one patient. Apr, 170
Mania associated with electroconvulsive therapy (letter with reply). July, 303–304
Manic syndrome following head injury: Another form of secondary mania. Jan, 29–30
The problem with parsimony: Mania and hyperthyroidism. July, 289–290
Trazodone-induced mania (letter). Oct, 423–424
Treatment of mania: A naturalistic study of electroconvulsive therapy versus lithium in 438 patients. Apr, 132–139
Treatment-resistant mania with primary hypothyroidism: A case of recovery after levothyroxine. Dec, 490–491
Triazolam-induced brief episodes of secondary mania in a depressed patient. Dec, 492–493

MAO Inhibitors
MAOI reaction with powdered protein dietary supplement (letter). Dec, 499
Mysterious hypertensive episodes (letter with reply). July, 304

Refractory depression treated with high doses of a monoamine oxidase inhibitor. Jan, 31–32
Treatment of MAOI hypertensive crisis with sublingual nifedipine. June, 249–250

Medroxyprogesterone Acetate
Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia. Sept, 368–370

Melancholia
Response to treatment in primary and secondary depression (letter). Sept, 386–387

Memory
A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Sept, Suppl, 20–23
Anxiolytics and memory: A comparison of lorazepam and alprazolam. Apr, 158–160

Meningoencephalitis
A case of catatonia induced by bacterial meningoencephalitis. Dec, 489–490

Mental Disorders
Cognitive disabilities: Measuring the social consequences of mental disorders. May, 185–190
Viral antibodies and interferon in acute psychiatric disorders. May, 194–196

Methadone
A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. Nov, 442–444

Mesoridazine
Complete heart block associated with mesoridazine and lithium combination (letter). Mar, 123
Mesoridazine and thioridazine (letter). Aug, 344

Methylene Blue
Methylene blue: A reliable and practical marker for validating compliance on the DST. June, 224–229

Methylphenidate
The effect of methylphenidate on school grades in children with attention deficit disorder with hyperactivity: A preliminary report. Mar, 112–114

Metoclopramide
Metoclopramide and depression (letter with reply). Jan, 38

Metoprolol
Metoprolol in the treatment of neuroleptic-induced tremor: Case report. Sept, 378

Midazolam
Midazolam in acute psychotic patients with hyperarousal. July, 291–292

Modified Mini-Mental State (3MS) Examination
The Modified Mini-Mental (3MS) Examination. Aug, 314–318

Multiple Personality Disorder
Multiple personality disorder? (letter with reply). Apr, 174

Myoclonus
Myoclonus and episodic delirium associated with phenelzine: A case report. Aug, 340–341

Neurochemistry
Recent advances in the neurochemistry of Alzheimer's disease. May, Suppl, 23–30

Neuroleptic Malignant Syndrome
A case of nonneuroleptic malignant syndrome. July, 287–288
Bromocriptine treatment of neuroleptic malignant syndrome. Feb, 69–73
ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. Mar, 102–105
Neuroleptic malignant syndrome: Physiological and laboratory findings in a series of nine cases. Aug, 328–333

Neuroleptics see Tranquilizing Agents, Major

Neuropharmacology
Neuropharmacology of the extrapyramidal system. Sept, Suppl, 7–12

Nifedipine
Treatment of MAOI hypertensive crisis with sublingual nifedipine. June, 249–250

Occupational Therapy
Cognitive disabilities: Measuring the social consequences of mental disorders. May, 185–190

Organic Mental Disorders
Carbamazepine in frontal lobe syndrome: Two more cases (letter). Nov, 456
Diagnosis of intermediate-duration and subacute organic mental disorders in abstinent alcoholics. Aug, 319–323

Outcome
Treatment and outcome in secondary depression: A naturalistic study of 1087 patients. Nov, 438–441
Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. July, 263–267

Outpatients
A fixed-dose clinical trial of fluoxetine in outpatients with major depression. Oct, 406–408
An outpatient evaluation of phenelzine and imipramine. Apr, 143–146
Comparison of alprazolam and imipramine for treatment of outpatient depression. Jan, 15–19
Serum neuroleptic levels, prolactin levels, and relapse: A two-year study of schizophrenic outpatients. Apr, 151–154
Treatment of outpatients with borderline personality disorder. Aug, Suppl, 32–35

Oxymetazoline
A case of panic disorder precipitated by oxymetazoline withdrawal. July, 293

Panic Attacks: See also Anxiety
Clonazepam: A review of open clinical trials. Oct, Suppl, 12–14
Hyperventilation and panic attacks. Nov, 435–437
Medical evaluation of panic attacks. Aug, 309–313
Misrepresenting uncontrolled clinical observations as "research" (letter with reply). July, 301–302
Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Feb, 55–59

Panic Disorder
A case of panic disorder precipitated by oxymetazoline withdrawal. July, 293
Alprazolam treatment for panic disorder (letter with reply). July, 301
Clonazepam in the treatment of prepubertal children with panic-like symptoms. Oct, Suppl, 38–41
Clonazepam versus alprazolam in the treatment of panic disorder: Interim analysis of data from a prospective, double-blind, placebo-controlled trial. Oct, Suppl, 16–19
Hypertension in the black population (letter). Sept, 387
Past and current thyroid function in subjects with panic disorder. Dec, 473–476
Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. Oct, Suppl, 22–26
Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Feb, 55–59
Three cases of overlap between panic disorder, social phobia, and agoraphobia. Nov, 452–453
Verapamil in the treatment of irritable bowel syndrome (letter). Sept, 388

Parsimony
The problem with parsimony: Mania and hyperthyroidism. July, 289–290

Personality Development
An XX male with schizophrenia: A case of personality development and illness similar to that in XXY males. Sept, 379–380

Personality Disorders: See also Borderline Personality Disorder
Prognostic validity of self-report and interview measures of personality disorder in depressed patients. Dec, 468–472

Pharmacokinetics
Clonazepam pharmacokinetics, brain uptake, and receptor interactions. Oct, Suppl, 4–9

Pharmacology
Pharmacologic properties of serotonergic agents and antidepressant drugs. Mar, Suppl, 5–11
Serotonin-norepinephrine receptor interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders. Mar, Suppl, 12–18

Phencyclidine
Blunting of TSH response to TRH in chronic cocaine and phencyclidine abusers. Jan, 25–26
Phencyclidine-associated psychosis (letter). Sept, 386

Phenelzine
An outpatient evaluation of phenelzine and imipramine. Apr, 143–146
Hypomania related to phenelzine and isoetharine interaction in one patient. Apr, 170
Myoclonus and episodic delirium associated with phenelzine: A case report. Aug, 340–341
Pretreatment dexamethasone suppression test as a predictor of response to phenelzine. Dec, 480–482
Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Feb, 55–59

Phenytoin
Desipramine and phenytoin: A potential drug interaction of therapeutic relevance (letter). Sept, 387–388

Phobic Disorders
Three cases of overlap between panic disorder, social phobia, and agoraphobia. Nov, 452–453

Phototherapy
Treatment of seasonal affective disorder with morning light. Nov, 447–448

PIP Syndrome
PIP syndrome (letter with reply). Apr, 173

Piracetam
Piracetam for drug-induced dyskinesia (letter). June, 255

Polydipsia
Coexisting central diabetes insipidus and psychogenic polydipsia. Feb, 75–76

Posttraumatic Stress Disorder
Alprazolam in the treatment of posttraumatic stress disorder (letter). May, 216–217
Biological markers of affective disorders and posttraumatic stress disorder: A pilot study with desipramine. Sept, 366–367

Prader-Willi Syndrome
Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient (letter). Oct, 423

Prediction
Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. Sept, 363–365
Prediction of therapeutic lithium dose: Comparison and improvement of current methods. July, 284–286
Psychobiologic predictors of suicide. Dec, Suppl, 39–43

Premenstrual Syndrome
PMS and rapid-cycling BAD (letter with reply). July, 300

Priapism
Priapism associated with thiothixene, chlorpromazine, and thioridazine (letter). May, 216
Trazodone and priapism. June, 244–245

Propranolol
Aggressive behavior in Huntington's disease: Treatment with propranolol. Mar, 106–108
Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: A double-blind trial. Sept, 355–358
Paradoxical aggressive effect of propranolol in a patient with Huntington's disease (letter). Sept, 385–386

Pseudocholinesterase
Serum pseudocholinesterase in state anxiety. May, 204–206

Psychomotor Agitation
Midazolam in acute psychotic patients with hyperarousal. July, 291–292

Psychomotor Performance
Cognitive disabilities: Measuring the social consequences of mental disorders. May, 185–190
Effects of minor tranquilizers and antidepressants on psychomotor performance. Dec, Suppl, 22–28

Psychopharmacology
Psychopharmacology of borderline personality disorder: A review. Aug, Suppl, 15–22
Psychosexual Disorders
Impotence associated with compulsive gambling. Mar, 115–116
Psychosis
A case of psychosis and delirium following withdrawal from triazolam. Apr, 168–169
Brief reactive psychosis. Aug, 324–327
Midazolam in acute psychotic patients with hyperarousal. July, 291–292
Phencyclidine-associated psychosis (letter). Sept, 386
Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. May, 197–200
Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. July, 263–267
Psychotropic Drugs
Legal liability with psychotropic drug use: Extrapyramidal syndromes and tardive dyskinesia. Sept, Suppl, 28–33
P.R.N. medications in child state hospital inpatients. Sept, 351–354
Rating Scales
A comparison of self-reported versus clinician-rated symptoms in depression. June, 246–248
Evaluation of sexual dysfunction. May, 191–193
Receptor Studies
Clonazepam pharmacokinetics, brain uptake, and receptor interactions. Oct, Suppl, 4–9
Receptor alterations associated with serotonergic agents: An autoradiographic analysis. Mar, Suppl, 19–25
Serotonin-norepinephrine receptor interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders. Mar, Suppl, 12–18
Renal Failure
Clonazepam in the treatment of bipolar disorder in patients with non-lithium-induced renal insufficiency (letter). Oct, 424
Rhabdomyolysis and acute renal failure (letter with reply). July, 299
Research Design
Misrepresenting uncontrolled clinical observations as "research" (letter with reply). July, 301–302
Restraint, Physical
Preventive aggression devices (PADS): Ambulatory restraints as an alternative to seclusion. Oct, 401–405
Rhabdomyolysis
Rhabdomyolysis and acute renal failure (letter with reply). July, 299
Schizophrenia
An XX male with schizophrenia: A case of personality development and illness similar to that in XXY males. Sept, 379–380
Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. Mar, 94–97
Diazepam in a patient with chronic schizophrenia complicated by agoraphobia. Jan, 33–34
Hydergine for schizophrenia (letter). Jan, 39–40
Hypothermia caused by antipsychotic drugs in a schizophrenic patient. Feb, 77–78
Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. Sept, 363–365
Serum neurolepic levels, prolactin levels, and relapse: A two-year study of schizophrenic outpatients. Apr, 151–154
The reassessment of chronic patients previously diagnosed as schizophrenic. Nov, 430–434
Seasons
Treatment of seasonal affective disorder with morning light. Nov, 447–448
Sedative Hypnotics: See also specific drugs
Seizures
Seizures following triazolam withdrawal despite benzodiazepine treatment. Oct, 418–419
Serotonin Irritation Syndrome
Serotonin irritation syndrome (letter with reply). May, 217
Serotonin
Clinical experience with serotonin reuptake inhibiting antidepressants. Mar, Suppl, 26–30
Introduction: Serotonin: A reappraisal. Mar, Suppl, 3–4
Pharmacologic properties of serotonergic agents and antidepressant drugs. Mar, Suppl, 5–11
Receptor alterations associated with serotonergic agents: An autoradiographic analysis. Mar, Suppl, 19–25
Serotonin-norepinephrine receptor interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders. Mar, Suppl, 12–18
Sex Deviations
Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia. Sept, 368–370
Sexual Dysfunction
Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. May, 201–203
Evaluation of sexual dysfunction. May, 191–193
Side Effects: See also specific drugs and Extrapyramidal Side Effects
A case of psychosis and delirium following withdrawal from triazolam. Apr, 168–169
Amoxapine-induced cognitive impairment in two patients. Apr, 166–167
Complete heart block associated with mesoridazine and lithium combination (letter). Mar, 123
Desipramine and weight gain (letter). Dec, 498–499
Erythema multiforme major in a patient treated with carbamazepine. Oct, 416–417
Hypothermia caused by antipsychotic drugs in a schizophrenic patient. Feb, 77–78
Imipramine and tinnitus. Mar, 109–111
Imipramine and tinnitus (letters with reply). Dec, 496
Lithium-induced akathisia (letter). Feb, 81
MAOI reaction with powdered protein dietary supplement (letter). Dec, 499
Management of antidepressant-induced side effects: A practical guide for the clinician. Jan, 3–8
Metoprolol in the treatment of neuroleptic-induced tremor: Case report. Sept, 378
Myoclonus and episodic delirium associated with phenelzine: A case report. Aug, 340–341
Paradoxical aggressive effect of propranolol in a patient with Huntington's disease (letter). Sept, 385–386
Seizures following triazolam withdrawal despite benzodiazepine treatment. Oct, 418–419
Successful treatment course with carbamazepine despite initial significant leukopenia: Case report. Aug, 338–339
Testicular swelling associated with desipramine. June, 251–252
The effect of desipramine on body weight in depression. Jan, 27–28
Trazodone and priapism. June, 244–245
Trazodone withdrawal and formication (letter). Sept, 385
Trazodone-induced mania (letter). Oct, 423–424
Triazolam-induced brief episodes of secondary mania in a depressed patient. Dec, 492–493
Two cases of benzodiazepine toxicity in children. Nov, 450–452
Sleep Disorders
A case of parasomnia at REM sleep onset. Oct, 414–415
Sleep apnea and hypothyroidism presenting as depression in two patients. Apr, 164–165
Treatment of coexistent night-terrors and somnambulism in adults with imipramine and diazepam. May, 209–210
Social Adjustment
Cognitive disabilities: Measuring the social consequences of mental disorders. May, 185–190
Solvents
Psychiatric correlates of chronic solvent abuse. Aug, 334–337
Stomatitis, Aphthous
Are tricyclic antidepressants effective for aphthous ulcers? (letter). June, 256
Stuttering
Carbamazepine treatment for stuttering (letter). Jan, 39
Substance Abuse
A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. Nov, 442–444
Blunting of TSH response to TRH in chronic cocaine and phencyclidine abusers. Jan, 25–26
Cocaine abuse and adult attention deficit disorder. Sept, 376–377
Eating disorders and cocaine abuse: A survey of 259 cocaine abusers. Feb, 47–50
Phencyclidine-associated psychosis (letter). Sept, 386
Psychiatric correlates of chronic solvent abuse. Aug, 334–337
Substance Withdrawal Syndrome
A case of panic disorder precipitated by oxymetazoline withdrawal. July, 293
Suicide
Clinical epidemiology of suicide. Dec, Suppl, 33–38
Lest treatment abet suicide. Dec, Suppl, 44–54
Psychobiologic predictors of suicide. Dec, Suppl, 39–43
Suicide risk prediction by computer interview: A prospective study. Dec, 464–467
Surgery
Postcardiotomy confusion and sleep loss. Nov, 445–446
Symptom Questionnaire
A symptom questionnaire. July, 268–274
Tarasoff
Assessing dangerousness and responding appropriately: *Hedlund* expands the clinician's liability established by *Tarasoff*. Jan, 9–12
Tardive Dyskinesia
Comparison of severe and mild tardive dyskinesia: Implications for etiology. Sept, 359–362
Legal liability and psychotropic drug use: Extrapyramidal syndromes and tardive dyskinesia. Sept, Suppl, 28–33
Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. July, 263–267
Tests, Psychological
The Modified Mini-Mental (3MS) Examination. Aug, 314–318
Thioridazine
Mesoridazine and thioridazine (letter). Aug, 344
Priapism associated with thiothixene, chlorpromazine, and thioridazine (letter). May, 216
Thiothixene
Priapism associated with thiothixene, chlorpromazine, and thioridazine (letter). May, 216
Thyroid Disorders
Sleep apnea and hypothyroidism presenting as depression in two patients. Apr, 164–165
Treatment-resistant mania with primary hypothyroidism: A case of recovery after levothyroxine. Dec, 490–491
Thyroid Function Tests
Past and current thyroid function in subjects with panic disorder. Dec, 473–476
Thyroxine
Treatment-resistant mania with primary hypothyroidism: A case of recovery after levothyroxine. Dec, 490–491
Thytropin-Releasing Hormone
Blunting of TSH response to TRH in chronic cocaine and phencyclidine abusers. Jan, 25–26
Tinnitus
Imipramine and tinnitus. Mar, 109–111
Imipramine and tinnitus (letters with reply). Dec, 496
Tourette Syndrome see Gilles de la Tourette's Disease
Tranquilizing Agents, Major: See also specific drugs
Behavioral toxicity of antipsychotic drugs. Sept, Suppl, 13–19
Clinical effectiveness of oral and parenteral rapid neuroleptization. Jan, 20–24

Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. Mar, 94–97
Dementia and antipsychotic drugs. May, Suppl, 16–18
Effectiveness of neuroleptics on behavioral symptoms in disturbed elderly patients (letter with reply). Dec, 497–498
Hypothermia caused by antipsychotic drugs in a schizophrenic patient. Feb, 77–78
Idiosyncratic neuroleptic response (letter). Aug, 344–345
Injection site leakage of depot neuroleptics: Intramuscular versus subcutaneous injection. June, 237–239; correction, Oct, 425
Mesoridazine and thioridazine (letter). Aug, 344
Metoprolol in the treatment of neuroleptic-induced tremor: Case report. Sept, 378
Neuroleptic treatment in the borderline patient: Advantages and techniques. Aug, Suppl, 26–30
Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. Sept, 363–365
Serum neuroleptic levels, prolactin levels, and relapse: A two-year study of schizophrenic outpatients. Apr, 151–154
Treatment of the elderly agitated patient. May, Suppl, 19–22
Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. July, 263–267
Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. May, 207–208

Tranquilizing Agents, Minor: See also specific drugs
Antianxiety therapy: Potential value of long-term treatment. Dec, Suppl, 7–11
Anxiolytics and memory: A comparison of lorazepam and alprazolam. Apr, 158–160
Consent and liability: Special problems with anxiolytics. Dec, Suppl, 29–32
Effects of minor tranquilizers and antidepressants on psychomotor performance. Dec, Suppl, 22–28
Long-term anxiolyic therapy: The issue of drug withdrawal. Dec, Suppl, 12–16

Tranylcypromine
High-dosage tranylcypromine in refractory depression (letter). Oct, 424–425
Tranylcypromine treatment of major depression (letter with reply). July, 303

Trazodone
Trazodone and priapism. June, 244–245
Trazodone withdrawal and formication (letter). Sept, 385
Trazodone-induced mania (letter). Oct, 423–424

Triazolam
A case of psychosis and delirium following withdrawal from triazolam. Apr, 168–169
Seizures following triazolam withdrawal despite benzodiazepine treatment. Oct, 418–419
Triazolam-induced brief episodes of secondary mania in a depressed patient. Dec, 492–493

Tricyclic Antidepressants
Are tricyclic antidepressants effective for aphthous ulcers? (letter). June, 256
Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. May, 197–200

Trifluoperazine
Management of behavioral symptoms in disturbed elderly patients: Comparison of trifluoperazine and haloperidol. June, 234–236

Verapamil
Lithium-verapamil: Further considerations (letter). Mar, 124
Verapamil: A new antimanic drug with potential interactions with lithium. Sept, 371–372
Verapamil in the treatment of irritable bowel syndrome (letter). Sept, 388

Violence
Patients who bring weapons to the psychiatric emergency room. June, 230–233

Water Intoxication
Coexisting central diabetes insipidus and psychogenic polydipsia. Feb, 75–76
PIP syndrome (letter with reply). Apr, 173

Withdrawal Symptoms see Substance Withdrawal Syndrome

Journal of Clinical Psychiatry

Author Index to Volume 48: January 1987 Through December 1987

Adams J see Mendoza R
Adams J see Dhillon AS
Adams KM see Grant I
Adams SF see Oster G
Addonizio G, Susman VL: ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. Mar, 102–105
Adler LA see McQuistion HL
Ahokas A, Rimón R, Koskiniemi M, Vaheri A, Julkunen I, Sarna S: Viral antibodies and interferon in acute psychiatric disorders. May, 194–196
Akiskal HS: Criteria for Review—And the Joys of a Book Review Editor, July, 297–298; Reviews of Frame J: *An Angel at My Table* and Rippere V, Williams R (eds): *Wounded Healers: Mental Health Workers' Experiences of Depression*, Apr, 171; The new biopsychiatry: A review of selected literature. Sept, 382–384
Alarcon RD: Review of Greenberg M, Szmukler G, Tantam D: *Making Sense of Psychiatric Cases*. May, 212–213
Albeck JH: Withdrawal and detoxification from benzodiazepine dependence: A potential role for clonazepam. Oct, Suppl, 43–48
Alexander PE: Replies to Miller F: Alprazolam treatment for panic disorder (letter); Dugas JE: Misrepresenting uncontrolled clinical observations as "research" (letter). July, 302
Allen CK, Allen RE: Cognitive disabilities: Measuring the social consequences of mental disorders. May, 185–190
Allen RE see Allen CK
Allen S see Dubovsky SL
Altman E see Chan CH
Alvarez WA see Johnson SB
Amado H see Munoz RA
Amiel M, Bryan S, Herjanic M: Clonazepam in the treatment of bipolar disorder in patients with nonlithium-induced renal insufficiency (letter). Oct, 424
Ananth J see Mendoza R
Andrade C, Gangadhar BN, Channabasavanna SM: Mania associated with electroconvulsive therapy (letter with reply). July, 303–304
Andrade C, Swaminath G, Gangadhar BN: Unilateral brief-pulse ECT and bilateral sinusoidal ECT (letter with reply). Jan, 38
Andriukaitis S see Chan CH
Annibali JA: Reply to Larocca FEF: Anorexia nervosa in a young man with Tourette's syndrome (letter). Mar, 123–124
Arana GW see Kraus RP
Arato M: Reviews of Freedman DX, Lourie RS, Meltzer HY, et al: *1986 Year Book of Psychiatry and Applied Mental Health*, Oct, 422; Maltsberger JT: *Suicide Risk: The Formulation of Clinical Judgment*, Nov, 454
Aronov NE: Review of Butcher JN (ed): *Computerized Psychological Assessment*. Dec, 495
Asnis GM see Rubinson EP
Ayyala M see Fricchione G
Babai MR see Price WA
Babiker IE: Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. Mar, 94–97
Badoe K see Lapierre YD
Balldin J, Berggren U, Rybo E, Kjellbo H, Lindstedt G: Treatment-resistant mania with primary hypothyroidism: A case of recovery after levothyroxine. Dec, 490–491
Balon R, Berchou R, Han H: Priapism associated with thiothixene, chlorpromazine, and thioridazine (letter). May, 216
Bartkó G, Herczeg I, Békésky M: Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. Sept, 363–365
Bartsch K see Gay M
Baxter LR Jr see Guze BH
Behar D see Vitiello B
Békésky M see Bartkó G
Beland F see Yassa R
Bell CC: Hypertension in the black population (letter). Sept, 387
Belzile L see Yassa R
Berchou R see Balon R
Berggren U see Balldin J
Berkman CS see Glazer WM
Berlant J see Rosenberg JG
Biederman J: Clonazepam in the treatment of prepubertal children with panic-like symptoms, Oct, Suppl, 38–41; Reply to Linet LS: Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine (letter), Nov, 456
Biggs J see Overall JE
Binder RL see McNiel DE; Rosenberg JG
Bingham SF see Powell BJ
Black DW, Winokur G, Nasrallah A: Treatment of mania: A naturalistic study of electroconvulsive therapy versus lithium in 438 patients, Apr, 132–139; Treatment and outcome in secondary depression: A naturalistic study of 1087 patients, Nov, 438–441
Blager F see Gay M
Borchardt CM, Popkin MK: Delirium and the resolution of depression. Sept, 373–375
Borenstein J see Reisberg B
Borison RL, Diamond BI: Neuropharmacology of the extrapyramidal system. Sept, Suppl, 7–12
Boshes R see Janicak PG
Brady JP: Review of Russell ML: *Behavioral Counseling in Medicine*. Mar, 121
Bresnahan D see Janicak PG
Brotman AW see Herman JB
Brown JA see Byerley WF
Brown WA see Faraone SV
Browne M see Lapierre YD
Bryan S see Amiel M
Buigues J, Vallejo J: Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Feb, 55–59
Burns A, Tune L: Amoxapine-induced cognitive impairment in two patients. Apr, 166–167
Burns R see Cohen MR
Bursten B: Review of Bulhan HA: *Frantz Fanon and the Psychology of Oppression*. Jan, 36–37
Butler PM see Pfefferbaum B
Byerley WF, Brown JA, Lebegue B: Treatment of seasonal affective disorder with morning light. Nov, 447–448
Byerley WF see Wamsley JK
Byrne S: Verapamil in the treatment of irritable bowel syndrome (letter). Sept, 388
Camille Y see Yassa R
Capwell R see Heritch AJ
Carlton PL, Manowitz P, McBride H, Nora R, Swartzburg M, Goldstein L: Attention deficit disorder and pathological gambling. Dec, 487–488
Carney MK see Kosten TR
Carpenter LL see Jacob M
Carr RE see Deicken RF
Carson RR: Review of Bluhm J: *When You Face the Chemically Dependent Patient: A Practical Guide for Nurses*. Dec, 494
Casper RC, Douglas Z, Staples N: Hyperprolactinemia in two patients with eating disorders. Mar, 119–120
Causey AR: Review of Baroff GS: *Mental Retardation: Nature, Cause, and Management, 2nd Ed.* Nov, 454
Chamberlin B: Review of Inwood DG (ed): *Recent Advances in Postpartum Psychiatric Disorders*. Mar, 121
Chan CH, Janicak PG, Davis JM, Altman E, Andriukaitis S, Hedeker D: Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. May, 197–200
Chandraiah S: PMS and rapid-cycling BAD (letter with reply). July, 300
Channabasavanna SM see Andrade C
Charney DS see Goodman WK
Chaturvedi SK: Metoprolol in the treatment of neuroleptic-induced tremor: Case report, Sept, 378; Piracetam for drug-induced dyskinesia (letter), June, 255
Cho SR see Lerer B
Chouinard G: Clonazepam in acute and maintenance treatment of bipolar affective disorder. Oct, Suppl, 29–36
Chui HC see Teng EL
Ciccone PE: Effectiveness of neuroleptics on behavioral symptoms in disturbed elderly patients (letter with reply). Dec, 497–498
Clark RL Jr see Stewart JT
Clary C, Schweizer E: Treatment of MAOI hypertensive crisis with sublingual nifedipine. June, 249–250
Cocores JA, Davies RK, Mueller . S, Gold MS: Cocaine abuse and adult attention deficit disorder. Sept, 376–377
Coffman JA: Review of Kirshner HS: *Behavioral Neurology: A Practical Approach*. Aug, 343
Coffman JA, Nasrallah HA, Lyskowski J, McCalley-Whitters M, Dunner FJ: Clinical effectiveness of oral and parenteral rapid neuroleptization. Jan, 20–24
Cohen LS, Rosenbaum JF: Clonazepam: New uses and potential problems. Oct, Suppl, 50–55
Cohen LS see Tesar GE

Cohen MR, Pary R, Burns R: Hydergine for schizophrenia (letter). Jan, 39–40
Cohen S, Fligner CL, Raisys VA, Luthi R, Dunner DL: A case of nonneuroleptic malignant syndrome. July, 287–288
Cole JO see Gardos G
Colla P see Hoes MJAJM
Cooper AJ: Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia, Sept, 368–370; Treatment of coexistent night-terrors and somnambulism in adults with imipramine and diazepam, May, 209–210
Copeland DR see Pfefferbaum B
Coryell W see Pfohl B
Cowdry RW: Psychopharmacology of borderline personality disorder: A review. Aug, Suppl, 15–22
Cubberley L see Risse SC
Cummings JL: Dementia syndromes: Neurobehavioral and neuropsychiatric features. May, Suppl, 3–8
Dager SR see Meibach RC
Daghestani AN: Impotence associated with compulsive gambling, Mar, 115–116; Phencyclidine-associated psychosis (letter), Sept, 386. See also **Orland RM**
Davidson J, Raft D, Pelton S: An outpatient evaluation of phenelzine and imipramine. Apr, 143–146
Davies P, Wolozin BL: Recent advances in the neurochemistry of Alzheimer's disease. May, Suppl, 23–30
Davies RK see Cocores JA
Davis JM see Chan CH; Janicak PG
Dawson TM see Wamsley JK
De Swart J see Hoes MJAJM
Deal N: Review of Wilson RR: *Don't Panic: Taking Control of Anxiety Attacks.* June, 253–254
DeAntonio M see Zetin M
Deicken RF, Carr RE: Testicular swelling associated with desipramine. June, 251–252
Dhib-Jalbut S, Hesselbrock R, Mouradian MM, Means ED: Bromocriptine treatment of neuroleptic malignant syndrome. Feb, 69–73
Dhillon AS, Adams JS: Lithium-related atrial premature contractions (letter). July, 305
Diamond BI see Borison RL
Dilsaver SC: Do benzodiazepines antagonize the actions of acetylcholine? (letter). Nov, 457
Dinwiddie SH, Zorumski CF, Rubin EH: Psychiatric correlates of chronic solvent abuse. Aug, 334–337
Djenderedjian AH: Review of Christodoulou GN (ed): *The Delusional Misidentification Syndromes*, Mar, 122. See also **Kauffman CD; Mendoza R**
Donachie ND see Overall JE
Douglas Z see Casper RC
Downs JM: Review of Casey DE, Chase TN, Christensen AV, Gerlach J (eds): *Dyskinesia: Research and Treatment (Psychopharmacology Supplementum 2).* Jan, 35
Drake ME Jr: A case of parasomnia at REM sleep onset. Oct, 414–415
Dubovsky SL, Franks RD, Allen S: Verapamil: A new antimanic drug with potential interactions with lithium. Sept, 371–372
Dugas JE: Misrepresenting uncontrolled clinical observations as "research" (letter with reply). July, 301–302
Dunner D see Meibach RC
Dunner DL see Cohen S
Dunner FJ see Coffman JA
Ellerbroek WC: Mysterious hypertensive episodes (letter with reply). July, 304
Emery CF see Gay M
Endres M see Muller N
Erdman HP, Greist JH, Gustafson DH, Taves JE, Klein MH: Suicide risk prediction by computer interview: A prospective study. Dec, 464–467
Esche I see Levitt AJ
Eth S see Mills MJ
Evans DL see Golden RN
Fabre LF, Putnam HP III: A fixed-dose clinical trial of fluoxetine in outpatients with major depression. Oct, 406–408
Fahs JJ see Walter-Ryan WG
Faillace LA, Overall JE: Reply to Thweatt RW: Alprazolam in treating secondary depression (letter). Dec, 497
Faillace LA see Overall JE
Falk WE see Weilburg JB
Famularo R, Fenton T: The effect of methylphenidate on school grades in children with attention deficit disorder without hyperactivity: A preliminary report. Mar, 112–114
Faraone SV, Brown WA, Laughren TP: Serum neuroleptic levels, prolactin levels, and relapse: A two-year study of schizophrenic outpatients. Apr, 151–154
Fava GA, Lisansky J: Response to treatment in primary and secondary depression (letter). Sept, 386–387
Fawcett RG: Erythema multiforme major in a patient treated with carbamazepine. Oct, 416–417
Feder R: Metoclopramide and depression (letter with reply). Jan, 38
Feighner JP: Buspirone in the long-term treatment of generalized anxiety disorder. Dec, Suppl, 3–6
Feldmann TB: Alprazolam in the treatment of posttraumatic stress disorder (letter). May, 216–217
Fenton T see Famularo R
Ferrell RB see McAllister TW
Ferris SH see Reisberg B
Finkel JA: Diazepam in a patient with chronic schizophrenia complicated by agoraphobia, Jan, 33–34; Reply to Lutz EG, Lutz MB, Lutz GE: Agoraphobia and paroxysmal cerebral dysrhythmia (letter). Sept, 389
Fish DN see Gupta BK
Fisman M: Classification of depression and dementia in the elderly (letter). Aug, 344
Fligner CL see Cohen S
Fogel BS, Haltzman S: Desipramine and phenytoin: A potential drug interaction of therapeutic relevance (letter). Sept, 387–388
Fogel BS see McNamara ME
Folgering H see Hoes MJAJM
Frank E see Jacob M
Frankenburg FR see Pope HG Jr
Franks RD see Dubovsky SL
Franssen E see Reisberg B
Free SM see Lovett WC
Freinhar JP see Johnson SB
Fricchione G, Kelleher S, Ayyala M: Coexisting central diabetes insipidus and psychogenic polydipsia. Feb, 75–76
Fuller RW: Pharmacologic properties of serotonergic agents and antidepressant drugs. Mar, Suppl, 5–11
Gabrielli WF Jr see Kumar R
Gadish DB: Hyponatremic effect of carbamazepine (letter with reply). Apr, 173
Gangadhar BN see Andrade C
Gardos G, Cole JO, Schniebolk S, Salomon M: Comparison of severe and mild tardive dyskinesia: Implications for etiology. Sept, 359–362
Garland EJ, Remick RA: Desipramine and weight gain (letter). Dec, 498–499
Garrick TR: Review of Dotevall G: *Stress and Common Gastrointestinal Disorders: A Comprehensive Approach.* Jan, 35–36
Garvey MJ, Hwang S, Teubner-Rhodes D, Zander J, Rhem C: Dextroamphetamine treatment of mania. Oct, 412–413
Gawin FH see Kosten TR
Gay M, Blager F, Bartsch K, Emery CF, Rosenstiel-Gross AK, Spears J: Psychogenic habit cough: Review and case reports. Dec, 483–486
Gelenberg AJ: Editor's clarification of Glazer WM, Maynard C, Berkman CS: Injection site leakage of depot neuroleptics: Intramuscular versus subcutaneous injection (48:237), Oct, 425; Introduction: The borderline patient, Aug, Suppl, 3–4; Sail into the future (editorial), July, 262; Treating extrapyramidal reactions: Some current issues, Sept, Suppl, 24–27
George A see Soloff PH
Georgotos A see Reisberg B
Gershon S see Lerer B; Yeragani VK
Giannini AJ, Malone DA, Loiselle RH, Price WA: Blunting of TSH response to TRH in chronic cocaine and phencyclidine abusers. Jan, 25–26
Giannini AJ, Piotrowski T: Reply to Warner RRP: Serotonin irritation syndrome (letter). May, 217
Giannini AJ see Price WA
Giles DE see Rush AJ
Glazer WM, Maynard C, Berkman CS: Injection site leakage of depot neuroleptics: Intramuscular versus subcutaneous injection, June, 237–239; correction, Oct, 425.
Glazer WM, Pino CD, Quinlan D: The reassessment of chronic patients previously diagnosed as schizophrenic. Nov, 430–434
Glickman L: Rhabdomyolysis and acute renal failure (letter with reply). July, 299
Gold MS see Cocores JA; Jonas JM
Golden RN, Evans DL: Imipramine and tinnitus (letter with reply). Dec, 496
Goldman JM: Resolution of hyperthyroidism after ECT therapy (letter with reply). July, 304–305
Goldman LS, Tiller JA: Hypomania related to phenelzine and isoetharine interaction in one patient. Apr, 170
Goldstein JA: Carbamazepine treatment for stuttering (letter). Jan, 39
Goldstein L see Carlton PL
Goldstein S: Three cases of overlap between panic disorder, social phobia, and agoraphobia, Nov, 452–453. See also **Tesar GE**
Goodman WK, Charney DS: A case of alprazolam, but not lorazepam, inducing manic symptoms. Mar, 117–118
Goodwin DW see Kumar R
Gordon AG: Imipramine and tinnitus (letter with reply). Dec, 496
Grant I, Reed R, Adams KM: Diagnosis of intermediate-duration and subacute organic mental disorders in abstinent alcoholics. Aug, 319–323
Greden JF see Tandon R
Greenblatt DJ, Miller LG, Shader RI: Clonazepam pharmacokinetics, brain uptake, and receptor interactions. Oct, Suppl, 4–9
Greist JH see Erdman HP
Grof P see Kraus RP
Grolnick S: Review of Larocca FEF (ed): *Eating Disorders: Effective Care and Treatment.* Nov, 455
Gross BH, Southard MJ, Lamb HR, Weinberger LE: Assessing dangerousness and responding appropriately: *Hedlund* expands the clinician's liability established by *Tarasoff.* Jan, 9–12
Grosser BI: Introduction: Serotonin: A reappraisal, Mar, Suppl, 3–4. See also **Wamsley JK**
Grota LJ: Review of Evered D, Clark S (eds): *Photoperiodism, Melatonin, and the Pineal.* June, 253
Grunhaus L see Tandon R
Gunderson JG, Zanarini MC: Current overview of the borderline diagnosis. Aug, Suppl, 5–11
Gupta BK, Fish DN, Yerevanian BI: Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient (letter). Oct, 423
Gustafson DH see Erdman HP
Guze BH, Baxter LR Jr, Rego J: Refractory depression treated with high doses of a monoamine oxidase inhibitor. Jan, 31–32
Hafken L: Review of APA Office of Economic Affairs: *An Economic Survival Manual for Private Practice Psychiatrists.* Jan, 37
Haier RJ see Kauffman CD
Hall DD see Small JG
Haltzman S see Fogel BS
Han H see Balon R
Harrell RG, Othmer E: Postcardiotomy confusion and sleep loss. Nov, 445–446
Harrop DS: Idiosyncratic neuroleptic response (letter). Aug, 344–345
Harsch HH: Neuroleptic malignant syndrome: Physiological and laboratory findings in a series of nine cases. Aug, 328–333
Harvey KJ see Kraus RP
Hashimoto H see Noto T
Hedeker D see Chan CH

Heiman MF: Review of Bloch S, Crouch E: *Therapeutic Factors in Group Psychotherapy.* Feb, 80
Henderson M see Yassa R
Hendrix EM: Review of Schwartz MF, Carter GL: *You Can Stop Stuttering.* Feb, 79
Herczeg I see Bartko G
Heritch AJ, Capwell R, Roy-Byrne PP: A case of psychosis and delirium following withdrawal from triazolam. Apr, 168–169
Herjanic M see Amiel M
Herman JB, Brotman AW, Rosenbaum JF: Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. Oct, Suppl, 22–26
Herman JB see Tesar GE
Hesselbrock R see Dhib-Jalbut S
Himmelhoch JM: Lest treatment abet suicide. Dec, Suppl, 44–54
Hiser W See Rush AJ
Hoes MJAJM, Colla P, van Doorn P, Folgering H, de Swart J: Hyperventilation and panic attacks. Nov, 435–437
Hoff J: Multiple personality disorder? (letter with reply). Apr, 174
Holden K see Overall JE
Hollister LE see Warner MD
Holmes VF see Menza MA
Horn E see Lapierre YD
Hudson JI see Pope HG Jr
Huey L see Schuckit MA
Huse DM see Oster G
Hux M see Kraus RP
Hwang S see Garvey MJ
Hyatt S see Munoz RA
Imbimbo J see Oster G
Ishiki D see Meibach RC
Ito N see Okada F
Jacob M, Frank E, Kupfer DJ, Carpenter LL: Recurrent depression: An assessment of family burden and family attitudes. Oct, 395–400
Jacobs M see Overall JE
Janicak PG see Chan CH
Janicak PG, Pandey GN, Sharma R, Boshes R, Bresnahan D, Davis JM: Pretreatment dexamethasone suppression test as a predictor of response to phenelzine. Dec, 480–482
Jefferson JW: Review of Lazarus JH, Collard KJ: *Endocrine and Metabolic Effects of Lithium.* Mar, 121–122
Joffe RT see Levitt AJ
Johnson SB, Alvarez WA, Freinhar JP: Reply to Glickman L: Rhabdomyolysis and acute renal failure (letter). July, 299–300
Jonas JM, Gold MS, Sweeney D, Pottash ALC: Eating disorders and cocaine abuse: A survey of 259 cocaine abusers. Feb, 47–50
Jonas JM see Pope HG Jr
Jos CJ: Replies to Wilson WH: PIP syndrome (letter); Gadish DB: Hyponatremic effect of carbamazepine (letter), Apr, 173–174
Josepii AB, O'Leary DH: Anterior cortical atrophy in Fregoli syndrome. Oct, 409–411
Julkunen I see Ahokas A
Kamimura H see Noto T
Kauffman CD, Reist C, Djenderedjian A, Nelson JN, Haier RJ: Biological markers of affective disorders and posttraumatic stress disorder: A pilot study with desipramine. Sept, 366–367
Kaye MS see Van Rybroek GJ
Kellams JJ see Small JG
Kelleher S see Fricchione G
Kellner R: A symptom questionnaire. July, 268–274
Kemperman CJF, Kuilman M, Njio LKF: Serum potassium levels and adrenergic activation (letter). Nov, 457
Keshavan MS see Veragani K
Kjellbo H see Balldin J
Klein MH see Erdman HP
Klerman GL: Clinical epidemiology of suicide, Dec, Suppl, 33–38. See also **Riess H**
Koskiniemi M see Ahokas A
Kosten TR, Schumann B, Wright D, Carney MK, Gawin FH: A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. Nov, 442–444
Kraus RP, Grof P, Arana GW, Workman RJ, Harvey KJ, Hux M: Methylene blue: A reliable and practical marker for validating compliance on the DST. June, 224–229
Kringlen E: Review of Beahrs JD: *Limits of Scientific Psychiatry: The Role of Uncertainty in Mental Health.* Dec, 494
Kuhlman TL see Van Rybroek GJ
Kuilman M see Kemperman CJF
Kumar R, Mac DS, Gabrielli WF Jr, Goodwin DW: Anxiolytics and memory: A comparison of lorazepam and alprazolam. Apr, 158–160
Kupfer DJ see Jacob M
Kuyumjian R: Review of Pedersen P (ed): *Handbook of Cross-Cultural Counseling and Therapy.* Jan, 37
Lader M: Long-term anxiolytic therapy: The issue of drug withdrawal. Dec, Suppl, 12–16
Lamb HR see Gross BH
Lampe TH see Raskind MA; Risse SC
Lapierre YD, Browne M, Horn E, Oyewumi LK, Sarantidis D, Roberts N, Badoe K, Tessier P: Treatment of major affective disorder with fluvoxamine. Feb, 65–68
Larocca FE: Review of Goodwin DW: *Anxiety.* Jan, 35
Larocca FEF: Anorexia nervosa in a young man with Tourette's syndrome (letter with reply), Mar, 123; Review of Gilbert S: *Pathology of Eating: Psychology and Treatment,* Oct, 421–422
Laughren TP see Faraone SV
Lebegue B see Byerley WF
Lee SR: Review of Johnson VE: *Intervention: How to Help Someone Who Doesn't Want Help.* Aug, 342–343
Lennhoff M: Trazodone-induced mania (letter). Oct, 423–424
Leong S see McQuistion HL
Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S: Carbamazepine versus lithium in mania: A double-blind study. Mar, 89–93
Lesser IM, Rubin RT, Lydiard RB, Swinson R, Pecknold J: Past and current thyroid function in subjects with panic disorder. Dec, 473–476
Levitt AJ, Joffe RT, Esche I, Sherret D: The effect of desipramine on body weight in depression. Jan, 27–28
Lewis DA, Nasrallah HA: Reply to Andrade C, Gangadhar BN, Channabasavanna SM: Mania associated with electroconvulsive therapy (letter). July, 304
Liebowitz MR: Tranylcypromine treatment of major depression (letter with reply). July, 303
Lindstedt G see Balldin J
Linet LS: Reply to Ellerbroek WC: Mysterious hypertensive episodes (letter), July, 304; Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine (letter with reply), Nov, 456
Lisansky J see Fava GA
Loiselle RH see Giannini AJ
Lovett WC: Reply to Ciccone PE: Effectiveness of neuroleptics on behavioral symptoms in disturbed elderly patients (letter). Dec, 498
Lovett WC, Stokes DK, Taylor LB, Young ML, Free SM, Phelan DG: Management of behavioral symptoms in disturbed elderly patients: Comparison of trifluoperazine and haloperidol. June, 234–236
Luthi R see Cohen S
Lutz EG, Lutz MB, Lutz GE: Agoraphobia and paroxysmal cerebral dysrhythmia (letter with reply). Sept, 388–389
Lutz GE see Lutz EG
Lutz MB see Lutz EG
Lydiard RB see Lesser IM
Lyskowski J see Coffman JA
Mac DS see Kumar R
Mahoney EM see Tesar GE
Maier GJ see Van Rybroek GJ
Malone DA see Giannini AJ
Mann JJ: Psychobiologic predictors of suicide. Dec, Suppl, 39–43
Manowitz P see Carlton PL
Marder SR see Van Putten T
Marhenke JD see Small JG
Maynard C see Glazer WM
McAllister TW, Price TRP, Ferrell RB: Reply to Andrade C, Swaminath G, Gangadhar BN: Unilateral brief-pulse ECT and bilateral sinusoidal ECT (letter). Jan, 38–39
McBride H see Carlton PL
McCabe RT see Wamsley JK
McCalley-Whitters M see Coffman JA
McConnell EJ see Wamsley JK
McEvoy JP: A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Sept, Suppl, 20–23
McNamara M see Tesar GE
McNamara ME, Southwick SM, Fogel BS: Sleep apnea and hypothyroidism presenting as depression in two patients. Apr, 164–165
McNiel DE, Binder RL: Patients who bring weapons to the psychiatric emergency room. June, 230–233
McQuistion HL, Adler LA, Leong S: Carbamazepine in frontal lobe syndrome: Two more cases (letter). Nov, 456
Means ED see Dhib-Jalbut S
Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR: Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: A double-blind trial. Sept, 355–358
Mendels J: Clinical experience with serotonin reuptake inhibiting antidepressants. Mar, Suppl, 26–30
Mendelsohn E see Modai I
Mendoza R, Djenderedjian AH, Adams J, Ananth J: Midazolam in acute psychotic patients with hyperarousal. July, 291–292
Menza MA, Murray GB, Holmes VF, Rafuls WA: Decreased extrapyramidal symptoms with intravenous haloperidol. July, 278–280
Meyendorff E see Lerer B
Miller F: Alprazolam treatment for panic disorder (letter with reply). July, 301
Miller LG see Greenblatt DJ
Miller NS see Powell BJ
Mills MJ, Eth S: Consent and liability: Special problems with anxiolytics, Dec, Suppl, 29–32; Legal liability with psychotropic drug use: Extrapyramidal syndromes and tardive dyskinesia, Sept, Suppl, 28–33
Milstein V see Small JG
Modai I, Mendelsohn E, Schwartz B: Serum pseudocholinesterase in state anxiety. May, 204–206
Moore N see Lerer B
Mounts ML see Stewart JT
Mouradian MM see Dhib-Jalbut S
Mueller PS see Cocores JA
Muller N, Endres M: An XX male with schizophrenia: A case of personality development and illness similar to that in XXY males. Sept, 379–380
Mullins D see Pfefferbaum B
Munoz RA, Amado H, Hyatt S: Brief reactive psychosis. Aug, 324–327
Murray GB see Menza MA
Nakajima T see Noto T
Nakao J see Noto T
Nasrallah A see Black DW
Nasrallah HA see Coffman JA; Lewis DA
Nastase C see Yassa R
Nathan RS see Soloff PH
Nelson JN see Kauffman CD
Njio LKF see Kemperman CJF
Nora R see Carlton PL
Noto T, Hashimoto H, Sugae S, Okamoto K, Nakao J, Kamimura H, Nakajima T: Hypothermia caused by antipsychotic drugs in a schizophrenic patient. Feb, 77–78
O'Leary DH see Joseph AB

Okada F, Ito N, Tsukamoto R: Two cases of transient partial amnesia in the course of transient global amnesia. Nov, 449–450
Okamoto K see Noto T
Olivier HR: Psychiatric aspects of Hansen's disease (leprosy). Dec, 477–479
Orland RM, Daghestani AN: A case of catatonia induced by bacterial meningoencephalitis. Dec, 489–490
Oster G, Russell MW, Huse DM, Adams SF, Imbimbo J: Accident- and injury-related health-care utilization among benzodiazepine users and nonusers. Dec, Suppl, 17–21
Othmer E see Harrell RG
Othmer E, Othmer SC: Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder, May, 201–203; Evaluation of sexual dysfunction, May, 191–193
Othmer SC see Othmer E
Overall JE, Biggs J, Jacobs M, Holden K: Comparison of alprazolam and imipramine for treatment of outpatient depression. Jan, 15–19
Overall JE, Donachie ND, Faillace LA: Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. Feb, 51–54
Overall JE see Faillace LA
Oyewumi LK see Lapierre YD
Pandey GN see Janicak PG
Pary R see Cohen MR
Pawluczyk S see Schneider LS
Peabody CA: Trazodone withdrawal and formication (letter), Sept, 385. See also **Warner MD**
Pearlman C: High-dosage tranylcypromine in refractory depression (letter). Oct, 424–425
Pearlman CA: Reply to Goldman JM: Resolution of hyperthyroidism after ECT therapy (letter). July, 305
Pecknold J see Lesser IM
Peele R: Review of Simon RI: *Clinical Psychiatry and the Law.* June, 254
Pelton S see Davidson J
Penick EC see Powell BJ
Perugi G: Review of Livesey PJ: *Learning and Emotion: A Biological Synthesis, Vol. 1: Evolutionary Processes.* Nov, 455
Pfefferbaum B, Butler PM, Mullins D, Copeland DR: Two cases of benzodiazepine toxicity in children. Nov, 450–452
Pfohl B, Coryell W, Zimmerman M, Stangl D: Prognostic validity of self-report and interview measures of personality disorder in depressed patients. Dec, 468–472
Phelan DG see Lovett WC
Pino CD see Glazer WM
Piotrowski T see Giannini AJ
Pitts FN Jr: Passage: An Editor in Chief (editorial). June, 223
Plon L see Zetin M
Pohl R see Veragani VK
Pollack MH: Clonazepam: A review of open clinical trials, Oct, Suppl, 12–14. See also **Tesar GE**
Pollack MH, Rosenbaum JF: Management of antidepressant-induced side effects: A practical guide for the clinician. Jan, 3–8
Pope HG Jr, Frankenburg FR, Hudson JI, Jonas JM, Yurgelun-Todd D: Is bulimia associated with borderline personality disorder? A controlled study. May, 181–184
Popkin MK see Borchardt CM
Pottash ALC see Jonas JM
Powell BJ, Read MR, Penick EC, Miller NS, Bingham SF: Primary and secondary depression in alcoholic men: An important distinction? Mar, 98–101
Price TRP see McAllister TW
Price WA: Reply to Chandraiah S: PMS and rapid-cycling BAD (letter), July, 300–301. See also **Giannini AJ**
Price WA, Babai MR: Antidepressant drug therapy for bulimia: Current status revisited (letter). Sept, 385
Price WA, Giannini AJ: Lithium-verapamil: Further considerations. Mar, 124
Price WA, Zimmer B: Lithium-induced akathisia (letter). Feb, 81
Pugh RL: Review of Will D, Wrate RM: *Integrated Family Therapy: A Problem-Centered Psychodynamic Approach.* Feb, 79–80
Pusakulich RL: Review of Filskov SG, Boll TJ (eds): *Handbook of Clinical Neuropsychology, Vol. 2.* Apr, 172
Putnam FW: Reply to Hoff J: Multiple personality disorder? (letter). Apr, 174
Putnam HP III see Fabre LF
Quinlan D see Glazer WM
Raft D see Davidson J
Rafuls WA see Menza MA
Ragheb M: Ibuprofen can increase serum lithium level in lithium-treated patients. Apr, 161–163
Ragheb MA: Aspirin does not significantly affect patients' serum lithium levels (letter). Oct, 425
Raisys VA see Cohen S
Raj A, Sheehan DV: Medical evaluation of panic attacks. Aug, 309–313
Raskind MA, Risse SC, Lampe TH: Dementia and antipsychotic drugs. May, Suppl, 16–18
Read MR see Powell BJ
Reed R see Grant I
Regan WM: Successful treatment course with carbamazepine despite initial significant leukopenia: Case report. Aug, 338–339
Rego J see Guze BH
Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotos A: Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. May, Suppl, 9–15
Reist C see Kauffman CD
Remick RA see Garland EJ
Rhem C see Garvey MJ
Ricculti AJ see Vitiello B
Richelson E: Mesoridazine and thioridazine (letter). Aug, 344
Rickels K: Antianxiety therapy: Potential value of long-term treatment. Dec, Suppl, 7–11
Riess H, Schwartz CE, Klerman GL: Manic syndrome following head injury: Another form of secondary mania. Jan, 29–30
Rifkin A: Extrapyramidal side effects: A historical perspective. Sept, Suppl, 3–6
Rihmer Z: Review of Wattis J and Church M: *Practical Psychiatry of Old Age.* Oct, 422
Rimón R see Ahokas A
Risse SC, Lampe TH, Cubberley L: Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. May, 207–208
Risse SC see Raskind MA
Roberts N see Lapierre YD
Rosenbaum JF: New uses for clonazepam in psychiatry: Concluding remarks, Oct, Suppl, 56; New uses for clonazepam in psychiatry: Introduction and overview, Oct, Suppl, 3. See also **Cohen LS; Herman JB; Pollack MH; Tesar GE**
Rosenberg JG, Binder RL, Berlant J: Prediction of therapeutic lithium dose: Comparison and improvement of current methods. July, 284–286
Rosenstiel-Gross AK see Gay M
Roy-Byrne PP see Heritch AJ
Rubin EH see Dinwiddie SH
Rubin RT see Lesser IM
Rubinson EP, Asnis GM: Major depression: Diagnostic problems and misconceptions (letter). June, 255–256
Rush AJ, Hiser W, Giles DE: A comparison of self-reported versus clinician-rated symptoms in depression. June, 246–248
Russell MW see Oster G
Rybo E see Balldin J
Saadah HA: A case of panic disorder precipitated by oxymetazoline withdrawal. July, 293
Sachs G see Weilburg JB
Sachs GS see Tesar GE
Salama AA: Complete heart block associated with mesoridazine and lithium combination (letter). Mar, 123
Salob SP see Reisberg B
Salomon M see Gardos G
Salzman C: Treatment of the elderly agitated patient. May, Suppl, 19–22
Sarantidis D see Lapierre YD
Sarna S see Ahokas A
Schneider LS, Syapin PJ, Pawluczyk S: Seizures following triazolam withdrawal despite benzodiazepine treatment. Oct, 418–419
Schniebolk S see Gardos G
Schuckit MA, Sweeney S, Huey L: Hyperactivity and the risk for alcoholism. July, 275–277
Schulz PM see Soloff PH
Schumann B see Kosten TR
Schuyler D: Review of Weiner MF: *Practical Psychotherapy.* June, 254
Schwartz B see Modai I
Schwartz CE see Riess H
Schweizer E see Clary C
Scott-Strauss AM: Review of Scott CD, Hawk J (eds): *Heal Thyself: The Health of Health Care Professionals.* May, 211–212
Shader RI see Greenblatt DJ
Sharma R see Janicak PG
Sheehan DV see Raj A
Sherret D see Levitt AJ
Shulman KI: Review of Jenike MA: *Handbook of Geriatric Psychopharmacology.* Oct, 422
Signer SF: Capgras' syndrome: The delusion of substitution. Apr, 147–150
Silver H: Physical complaints are part of the core depressive syndrome: Evidence from a cross-cultural study in Israel. Apr, 140–142
Siris SG: Akinesia and postpsychotic depression: A difficult differential diagnosis. June, 240–243
Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ: Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. July, 263–267
Smiley A: Effects of minor tranquilizers and antidepressants on psychomotor performance. Dec, Suppl, 22–28
Soloff PH: Neuroleptic treatment in the borderline patient: Advantages and techniques. Aug, Suppl, 26–30
Soloff PH, George A, Nathan RS, Schulz PM: Characterizing depression in borderline patients. Apr, 155–157
Southard MJ see Gross BH
Southwick SM see McNamara ME
Spears J see Gay M
Stangl D see Pfohl B
Staples N see Casper RC
Stewart JT: Paradoxical aggressive effect of propranolol in the patient with Huntington's disease (letter). Sept, 385–386
Stewart JT, Mounts ML, Clark JL Jr: Aggressive behavior in Huntington's disease: Treatment with propranolol. Mar, 106–108
Stokes DK see Lovett WC
Stone MH: Review of Wallerstein RS: *Forty-Two Lives in Treatment: A Study of Psychoanalysis and Psychotherapy.* May, 211
Strassman RJ: Review of Westermeyer J: *A Clinical Guide to Alcohol and Drug Problems.* Oct, 421
Sugae S see Noto T
Sulser F: Serotonin-norepinephrine receptor interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders. Mar, Suppl, 12–18
Surawicz FG: Review of Mueller WJ, Aniskiewicz S: *Psychotherapeutic Intervention in Hysterical Disorders.* Feb, 80
Susman VL see Addonizio G
Swaminath G see Andrade C
Swartz CM: Correction of lithium levels for dose and blood sampling times. Feb, 60–64
Swartzburg M see Carlton PL
Sweeney D see Jonas JM

Sweeney DR: Treatment of outpatients with borderline personality disorder. Aug, Suppl, 32–35
Sweeney S see Schuckit MA
Swinson R see Lesser IM
Syapin PJ see Schneider LS
Tandon R, Grunhaus L, Greden JF: Imipramine and tinnitus, Mar, 109–111; Replies to Golden RN, Evans DL; Gordon AG: Imipramine and tinnitus (letters). Dec, 496–497
Tashjian LD: Review of Barker P: *Basic Family Therapy, 2nd Ed.* Dec, 495
Taves JE see Erdman HP
Taylor LB see Lovett WC
Teng EL, Chui HC: The Modified Mini-Mental (3MS) Examination. Aug, 314–318
Tesar GE, Rosenbaum JF, Pollack MH, Herman JB, Sachs GS, Mahoney EM, Cohen LS, McNamara M, Goldstein S: Clonazepam versus alprazolam in the treatment of panic disorder: Interim analysis of data from a prospective, double-blind, placebo-controlled trial. Oct, Suppl, 16–19
Tessier P see Lapierre YD
Teubner-Rhodes D see Garvey MJ
Thweatt RW: Alprazolam in treating secondary depression (letter with reply). Dec, 497
Tiller JA see Goldman LS
Tondo L: Review of Winokur G, Clayton P (eds): *The Medical Basis of Psychiatry.* Nov, 454
Tsukamoto R see Okada F
Tullis KF: Review of Cermak TL: *Diagnosing and Treating Co-Dependence: A Guide for Professionals Who Work With Chemical Dependents, Their Spouses, and Children.* Oct, 421
Tune L see Burns A
Vaheri A see Ahokas A
Vallejo J see Bulgues J
Van Doorn P see Hoes MJAJM
Van Putten T, Marder SR: Behavioral toxicity of antipsychotic drugs. Sept, Suppl, 13–19
Van Rybroek GJ, Kuhlman TL, Maier GJ, Kaye MS: Preventive aggression devices (PADS): Ambulatory restraints as an alternative to seclusion. Oct, 401–405
VanValkenburg C: Reviews of Millon T, Klerman GL (eds): *Contemporary Directions in Psychopathology: Toward the DSM-IV,* Aug, 342; Stimmel B (ed): *Controversies in Alcoholism and Substance Abuse,* Apr, 171–172
Vitiello B, Ricciuti AJ, Behar D: P.R.N. medications in child state hospital inpatients. Sept, 351–354
Walter-Ryan WG, Fahs JJ: The problem with parsimony: Mania and hyperthyroidism. July, 289–290
Wamsley JK, Byerley WF, McCabe RT, McConnell EJ, Dawson TM, Grosser BI: Receptor alterations associated with serotonergic agents: An autoradiographic analysis. Mar, Suppl, 19–25
Warner MD, Peabody CA, Whiteford HA, Hollister LE: Trazodone and priapism. June, 244–245
Warner RRP: Serotonin irritation syndrome (letter with reply). May, 217
Weddington WW Jr: Reply to Feder R: Metoclopramide and depression (letter). Jan, 38
Weilburg JB, Sachs G, Falk WE: Triazolam-induced brief episodes of secondary mania in a depressed patient. Dec, 492–493
Weinberger LE see Gross BH
White J see White K
White K, White J: Reply to Liebowitz MR: Tranylcypromine treatment of major depression (letter). July, 303
White PD: Myoclonus and episodic delirium associated with phenelzine: A case report. Aug, 340–341
Whiteford HA see Warner MD
Williams RA: Review of Glenn MD, Weiner RD: *Electroconvulsive Therapy: A Programmed Text.* Jan, 36
Wilson LG see Meibach RC
Wilson WH: PIP syndrome (letter with reply). Apr, 173
Winokur G see Black DW
Wolozin BL see Davies P
Workman RJ see Kraus RP
Wright D see Kosten TR
Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F: Carbamazepine, diuretics, and hyponatremia: A possible interaction. July, 281–283
Yeragani VK, Pohl R, Keshavan MS, Gershon S: Are tricyclic antidepressants effective for aphthous ulcers? (letter). June, 256
Yerevanian BI see Gupta BK
Young ML see Lovett WC
Yurgelun-Todd D see Pope HG Jr
Zanarini MC see Gunderson JG
Zander J see Garvey MJ
Zetin M, Plon L, DeAntonio M: MAOI reaction with powdered protein dietary supplement (letter). Dec, 499
Zimmer B see Price WA
Zimmerman M see Pfohl B
Zorumski CF see Dinwiddie SH
Zung WWK: Effect of clorazepate on depressed mood in anxious patients. Jan, 13–14